Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/1999

01-12-1999 | Paper Report

Missing cancers at prevalence screen affects their size at incidence screen

Author: Jenny McCann

Published in: Breast Cancer Research | Issue 1/1999

Login to get access

Excerpt

Cancer detection rate is an important measure of screening performance. If cancers are missed at prevalence screen, and fail to present as interval cancers before the next screen is due, then their detection at incidence screen may artificially boost the detection rate at that screen. Such cancers might be expected to be larger than those detected at incidence screen but not present at prevalence screen. …
Literature
1.
Pandha HS, Martin LA, Rigg A, Hurst HC, Stamp GW, Sikora K, Lemoine NR: Breast cancer missed in the prevalent screening round: effect upon the size distribution of incident round detected cancers. J Med Screen. 1999, 6: 28-29.CrossRef
Metadata
Title
Missing cancers at prevalence screen affects their size at incidence screen
Author
Jenny McCann
Publication date
01-12-1999
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/1999
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-1999-66592

Other articles of this Issue 1/1999

Breast Cancer Research 1/1999 Go to the issue

Paper Report

17q aberrations in breast cancer

Paper Report

Protein expression mapping of normal human breast epithelium

Paper Report

Interaction of BRCA1 and AR genes in breast cancer risk

Paper Report

ErbB-4 dependent proliferation of ER+ breast cells

Paper Report

LOH in a transgenic model of breast cancer

Commentary

How many more breast cancer predisposition genes are there?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits